One study evaluated the growth-inhibitory activities of MRTX849C, in seven NSCLC cell lines carrying KRAS G12 mutations (three G12C and four non-G12C), and all non-G12C cell lines were resistant as expected, largely consistent with our results[55]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.